StemCells Profile

USD 0.04  4.38%
Last 1 Month(s)

StemCells Market Sensitivity

As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, StemCells will likely underperform.
One Month Beta |Analyze StemCells Inc Demand Trend
Check current 30 days StemCells correlation with market (NYSE)
β = 3.5704
StemCells Large BetaStemCells Inc Beta Legend

Selected StemCells Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

StemCells Against Markets

StemCells Leadership

Martin McGlynn CEO, Director, Member of Strategic Transactions Committee, CEO of Stemcells California Inc and President of Stemcells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
More Executives

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of StemCells to be traded at $0.8353 in 30 days

StemCells Daily Price Distribution

The median price of StemCells for the period between Tue, Sep 27, 2016 and Thu, Oct 27, 2016 is 1.04 with a coefficient of variation of 16.01. The daily time series for the period is distributed with a sample standard deviation of 0.17, arithmetic mean of 1.07, and mean deviation of 0.14. The Stock received some media coverage during the period.

StemCells Summary

StemCells Inc (STEM) is traded on Nasdaq Capital Markets in USA. It is located in CALIFORNIA, U.S.A and employs 74 people. StemCells is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 14.93 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 16.26 M outstanding shares of which 1.93 M shares are at this time shorted by private and institutional investors with about 1.62 trading days to cover. STEMCELLS INC currently holds about 2.45 M in cash with (31.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
StemCells Inc. a biopharmaceutical company engages in the research development and commercialization of cellbased therapeutics and related technologies. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameStemCells Inc
InstrumentUSA Stock
Business AddressNewark, CA
ExchangeNasdaq Capital Markets
Contact Number510 456 4000
Analyst Consensus
Piotroski F Score
Macroaxis Advice
CurrencyUSD - US Dollar
StemCells Corporate Directors
Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director
StemCells Alerts
Equity Alerts and Improvement Suggestions
StemCells Inc generates negative expected return over the last 30 days
StemCells Inc has some characteristics of a very speculative penny stock
StemCells Inc has high historical volatility and very poor performance
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company currently holds 9.3 M in liabilities with Debt to Equity (D/E) ratio of 1.6 which is about average as compared to similar companies. StemCells Inc has Current Ratio of 0.45 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.
This company reported previous year revenue of 118.23 K. Net Loss for the year was (25.65 M) with profit before overhead, payroll, taxes, and interest of 116.89 K.
STEMCELLS INC currently holds about 2.45 M in cash with (31.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Latest headline from StemCells Inc. Encourages Stockholders to Return Proxies Approving the ...
Corporate Filings
StemCells Corporate Filings
Financial Statements and Exhibits. Results of Operations and Financial Condition
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events
Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
Company Reports
StemCells Corporate Reports
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  
StemCells Earnings Estimates
StemCells Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  
Pair Trading
StemCells Pair Trading Analysis
Correlation analysis and pair trading evaluation for StemCells and Amgen Inc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation